Avadel Pharmaceuticals financials at a glance

+ Portfolio

The revenue of Avadel Pharmaceuticals is reported as 0.02796 billion Dollars in the fiscal year 2023. The earnings were -1.8 Dollars per share in 2023, which was 0 higher than 2022. And about -0.13984 billion Dollars are reported as free cash flow in the financials of Avadel Pharmaceuticals 2023. No dividends were paid to the shareholders of the Avadel Pharmaceuticals stock NasdaqGM:AVDL in the financial year 2023.

$27.96M

Revenue

$-1.80

Earnings Per Share

96.97%

Gross Margin %

$0.00M

Free Cash Flow

Revenue

27.96

Earnings Per Share

-1.80

Gross Margin %

96.97

Free Cash Flow

0.00

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018	2017	2016
Rev.	Revenue	N/A	$27.96M	$0.00M	$0.00M	$22.33M	$59.22M	$103.27M	$172.74M	$150.25M
GM %	Gross Margin %	98.20%	96.97%	0.00%	0.00%	74.29%	79.52%	83.04%	90.59%	91.18%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	-,164.15%	-28.42%	-58.64%	35.21%	29.50%
EPS	Earnings Per Share	$-2.17	$-1.80	$-1.80	$-1.32	$-0.66	$-0.68	$-1.99	$0.31	$-0.06
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0	0	0	0	0	0	0	0
Sha.	Shares	N/AM	90.58M	64.48M	59.03M	58.47M	46.4M	37.36M	37.95M	41.38M
OCF	Operating Cash Flow	N/A	$-,128.51M	$-70.30M	$-77.31M	$-48.73M	$-38.33M	$0.00M	$16.66M	$18.90M
FCF	Free Cash Flow	N/A	$-,139.84M	$-71.02M	$-77.34M	$-48.83M	$-38.36M	$0.00M	$16.07M	$17.70M
FCFS	Free Cash Flow Per Share	$-1.58	$-1.60	$-1.18	$-1.32	$-0.92	$-1.03	$-2.76	$-0.92	$0.43

Avadel Pharmaceuticals financials at a glance

Financials

Discover